Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity. The company is targeting the melanocortin-4 receptor (MC4R) pathway that is impaired due to genetic variants. This is a key biological pathway that regulates weight and hunger. A central element of Rhythm’s mission is to improve the understanding of these disorders and develop management strategies for patients who have no treatment options available to them. Rhythm was founded in 2008 and is based in Boston, MA. The company’s clinical development program is currently focused on several rare genetic disorders of obesity, all driven by genetic variants in the MC4R pathway.
Rhythm Pharmaceuticals
Unlock to Claim this listing
Add / Modify Company
Click to rate this company
[Total: 0 Average: 0]
Click here to sign in to vote
0.47
Overall Excellence Rating
Industry
Gas & Mining, OilCategory
Biotechnology ResearchESG/Ethical Impact
Rhythm Pharmaceuticals’ focus on developing therapies for rare genetic disorders could contribute to more efficient drug development processes, potentially reducing resource consumption associated with traditional treatments. The company implement environmentally responsible practices in its laboratories and operations, such as energy-efficient equipment and waste reduction measures. Rhythm Pharmaceuticals collaborate with research partners and institutions to share sustainable practices and collectively advance environmentally friendly initiatives in the biopharmaceutical industry. Rhythm Pharmaceuticals’ therapies significantly impact the lives of individuals with rare genetic disorders, improving their quality of life and overall health. The company’s focus on rare disorders increase access to effective treatments for patients with limited treatment options. Rhythm Pharmaceuticals’ governance structure includes a leadership team responsible for strategic decisions and ethical practices. The company uphold high ethical standards in its research activities, particularly concerning rare disease therapies and patient safety. Rhythm Pharmaceuticals emphasize transparent communication with stakeholders about its research progress, trial results, and ethical considerations. Rhythm Pharmaceuticals’ ESG efforts contribute to its long-term financial success by enhancing its reputation, attracting responsible investors, and improving operational efficiency. The company’s commitment to rare disease therapies lead to breakthrough treatments, driving market value and growth potential. By implementing sustainable practices, Rhythm Pharmaceuticals achieve cost savings through reduced resource consumption and streamlined operations. Strong ESG performance attract investors who prioritize companies with responsible and ethical business practices. Rhythm Pharmaceuticals’ commitment to patient safety ensures that clinical trials and therapies adhere to rigorous ethical standards. The company’s operations adhere to ethical guidelines and regulatory requirements for drug development and clinical research.
Eligible Awards
Coming Soon
Claim Your Award Badges
Do you work with Us
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer.
Awards Received
2023
Revenues
62000000.00
Website Traffic
Employee Rating
3.20
Customer Rating
Company Size
100-1000
ESG Risk Rating
3.00
We’re Happy to Help.
Do you have questions about your ranking, our projects, or why you’re not on the list?